Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$265.58
52-Week Range
Decision Context
Outperforms sector peers on capital efficiency. The peer comparison edge is a meaningful differentiator in the current competitive landscape.
Based on filing period ending Jun 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.63%
Accommodative
10-Year Treasury
4.47%
2026-06-01
Unemployment
4.2%
Near full employment
CPI Index
332.6
2026-06-01
M2 Money Supply
$23.1T
2026-05-01
The Federal Funds rate stands at 3.63% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.47%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 102.6; M2 money supply is $23.1T; CPI index stands at 332.6.
SWOT Analysis — JNJ
Inflationary BoomStrengths
Net Income: $26.8B (+90.6% YoY) — Profit grew 91% — the company kept more of each dollar earned.
EPS (Diluted): $11.03 (+90.5% YoY) — Earnings per share rose 91% — each share earned more.
Total Assets: $199.2B (+10.6% YoY) — Total assets grew 11% — the company's resource base expanded.
Revenue: $94.2B (+6.0% YoY) — Revenue grew 6% — the company sold more goods or services than the prior year.
Weaknesses
No material weaknesses flagged.
Opportunities
Gross Profit: $63.9B (+4.2% YoY) — Gross profit rose 4% — the spread between revenue and direct costs improved.
Threats
Current ratio of 1.03x — thin liquidity buffer against short-term obligations.
Financial Charts
Year-over-Year Changes
Net Income
$26.8B
was $14.1B
Profit grew 91% — the company kept more of each dollar earned.
EPS (Diluted)
$11.03
was $5.79
Earnings per share rose 91% — each share earned more.
Total Assets
$199.2B
was $180.1B
Total assets grew 11% — the company's resource base expanded.
Revenue
$94.2B
was $88.8B
Revenue grew 6% — the company sold more goods or services than the prior year.
Gross Profit
$63.9B
was $61.4B
Gross profit rose 4% — the spread between revenue and direct costs improved.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Current ratio of 1.03x — thin liquidity buffer against short-term obligations.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — JNJ
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade JNJ
Links open broker research pages. Not an endorsement or recommendation.
Research Johnson & Johnson
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.